At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Group Adrug
Likely dose
Group A 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Intravitreal Bevacizumab and Triamcinolone Acetonide With Intravitreal Bevacizumab Alone in Macular Edema Secondary to Central Retinal Vein Occlusion
In Brief
A clinical study evaluating Group A for Central Retinal Vein Occlusion With Macular Edema. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPakistan
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
Primary CompletionDec 2018
First PostedMar 2021
TodayJul 2026
First PostedMar 24, 2021
Enrollment StartJun 10, 2018
Primary CompletionDec 10, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.3 years ago
Interventions
Group Adrug
Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)